Meropenem injection — supplier from India to the UK, GCC and Africa.

Meropenem is supplied as 500mg and 1g lyophilised vials — the two standard hospital strengths across MHRA, EMA, SFDA, MOHAP, SAHPRA and BfArM labelling. The 500mg vial reconstitutes with 10ml water for injection and the 1g with 20ml; the solution can be used as a 3-5 minute IV bolus or further diluted in 0.9% NaCl or 5% glucose for a 15-30 minute infusion. Single-vial cartons are standard; 5- and 10-vial hospital outer packs are available against firm tender orders.

Yes. Multiple Indian WHO-GMP partner lines on the M Care roster hold current WHO Prequalification (WHO-PQ) on meropenem, which is the gating requirement for Global Fund, UNICEF Supply Division, GHSC-PSM and comparable UN procurement routes. Where a tender specifies prequalified supply we route to the WHO-PQ lines; where it doesn't, the broader WHO-GMP roster applies. The PQ status is confirmed against the WHO list at point of offer and the prequalification reference appears in the CoPP pack. See NGO and donor procurement.

Meropenem reduces valproate serum levels by 30-80% within 24 hours of the first dose — a clinically significant drop that can precipitate breakthrough seizures. Our destination-language pack inserts carry the interaction contraindication verbatim from the reference SmPC, and the standard pharmacist guidance is unambiguous: do not co-administer. Patients on valproate who need empirical meropenem should be switched to an alternative anticonvulsant (levetiracetam, phenytoin with level monitoring, or a benzodiazepine bridge) before the first meropenem dose — not after. The interaction is noted in the stewardship insert we ship alongside the product.

We routinely ship meropenem into the UK (licensed wholesale and MHRA Specials / named-patient import where the UK supply is constrained — intermittent shortage-register listings through 2023-2026), the GCC (UAE, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain — through licensed local importers), sub-Saharan Africa (Nigeria, Kenya, Ghana, South Africa — ICU tender and teaching-hospital supply, plus Global Fund procurement where the tender specifies WHO-PQ), and Germany (§72 AMG import channels with QP certification). We do not supply into India.

Every consignment ships with a batch-specific Certificate of Analysis (HPLC assay, related substances, water content by Karl Fischer, sterility per USP <71>, bacterial endotoxin per USP <85>, particulate matter), Method of Analysis, Certificate of Pharmaceutical Product (CoPP), WHO-GMP certificate, manufacturing licence, WHO-PQ confirmation where applicable, Certificate of Origin, destination-language PIL with valproate-interaction and seizure-risk warnings verbatim, temperature logs, and a carbapenem-stewardship reference insert. Full list under anti-infectives.

Most hospital formularies restrict meropenem prescribing to infectious-disease or microbiology approval — it is a carbapenem-reserve antibiotic. Procurement should reflect the stewardship draw-down, not bulk standing-order: we match batch size and delivery cadence to a realistic 3-6 month consumption projection and size the first order conservatively so shelf-life pressure does not force unnecessary prescribing. Where Carbapenem-Resistant Enterobacteriaceae (CRE) prevalence exceeds roughly 10% of the local antibiogram, empirical protocols increasingly pair meropenem with a novel beta-lactamase inhibitor; we flag the implication at quote stage.

For registered markets with stock on hand, dispatch is typically 5-10 working days from confirmed order. Made-to-order batches, 8-12 weeks inclusive of QC release (HPLC, water content, sterility, endotoxin) and destination-specific artwork approval — longer than a solid dosage form because each batch requires full sterility and endotoxin clearance before release. Air-freight to UK or GCC: 3-5 days; sea-freight to Africa: 18-28 days at below-25°C, with continuous in-transit logging and on-arrival inspection.